Compare Quest Diagnostics Inc (DGX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ProShares Ultra Gold ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: Quest Diagnostics Inc is far larger — about 35.6× ProShares Ultra Gold ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ProShares Ultra Gold ETF for 23 Days on average.
| DGX | UGL | |
|---|---|---|
Market Cap | $25.48B | $716.59M |
Volume | 941,866 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $85.62 |
52-Week Low | $173.49 | $42.79 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
UGL is trading at $45.08, up 1.46% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key support at $44 and resistance at $46. Recent market sentiment reflects uncertainty around Federal Reserve policy and Treasury yield pressures affecting gold-related assets.
The outlook remains cautious as UGL navigates macroeconomic pressures including interest rate uncertainty and dollar strength. While technical indicators suggest near-term weakness, the stock's proximity to support levels may offer tactical opportunities for patient investors. Key risks include continued Fed hawkishness and gold price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
